Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes. METHOD: In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary efficacy measure was change from baseline in Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of patients with/without attention-deficit/hyperactivity disorder (ADHD) and with/without stimulant use were performed. RESULTS: The mean difference in asenapine versus placebo in YMRS was -3.2 (p = .0008), -5.3 (p < .001), and -6.2 (p < .001) for asenapine 2.5, 5, and 10 mg b.i.d., respectively. Treatment-emergent adverse events with an incidence ≥5% and at least twice placebo were somnolence, sedation, hypoesthesia oral, paresthesia oral, and increased appetite. The asenapine groups had a higher incidence of ≥7% weight gain (range, 8.0%-12.0%) versus placebo (1.1%; p < .05). The mean change from baseline in fasting insulin was larger for patients treated with asenapine than those with placebo (asenapine 2.5 mg b.i.d.: 73.375 pmol/L; asenapine 5 mg b.i.d.: 114.042 pmol/L; asenapine 10 mg b.i.d.: 59.846 pmol/L; placebo: 3.690 pmol/L). The mean changes from baseline for lipid parameters and glucose were also larger in asenapine groups than in the placebo group. No safety differences were observed with respect to ADHD and stimulant use. CONCLUSION: All asenapine doses versus placebo were superior based on change in YMRS at day 21. Asenapine was generally well tolerated in patients aged 10 to 17 years with bipolar I disorder in manic or mixed states. Increases in weight and fasting insulin were associated with asenapine. Clinical trial registration information-Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder; http://clinicaltrials.gov; NCT01244815.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Perlis, R. H., Miyahara, S., Marangell, L. B., Wisniewski, S. R., Ostacher, M., DelBello, M. P., Bowden, C. L., Sachs, G. S., & Nierenberg, A. A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.022 · Cited by 852
Early-Onset Bipolar Disorder and Treatment Delay Are Risk Factors for Poor Outcome in Adulthood
Post, R. M., Leverich, G. S., Kupka, R. W., Keck, P. E., McElroy, S. L., Altshuler, L. L., Frye, M. A., Luckenbaugh, D. A., Rowe, M., Grunze, H., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04994yel · Cited by 360
Research works printed but not linked: 24
- Perlis, 2009, Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study, Bipolar Disord, 11, 391, 10.1111/j.1399-5618.2009.00686.x · DOI · Paper page
- Birmaher, 2006, Clinical course of children and adolescents with bipolar spectrum disorders, Arch Gen Psychiatry, 63, 175, 10.1001/archpsyc.63.2.175 · DOI · Paper page
- Birmaher, 2013, Bipolar disorder in children and adolescents, Child Adolesc Ment Health, 18, 140, 10.1111/camh.12021 · DOI · Paper page
- Pavuluri, 2010, Double-blind randomized trial of risperidone vs. divalproex in pediatric bipolar disorder, Bipolar Disord, 12, 593, 10.1111/j.1399-5618.2010.00850.x · DOI
- Findling, 2009, Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study, J Clin Psychiatry, 70, 1441, 10.4088/JCP.09m05164yel · DOI · Paper page
- Delbello, 2002, A double-blind, randomized, placebo controlled study of quetiapine as adjunctive treatment for adolescent mania, J Am Acad Child Adolesc Psychiatry, 41, 1216, 10.1097/00004583-200210000-00011 · DOI · Paper page
- Tohen, 2007, Olanzapine vs. placebo in the treatment of adolescents with bipolar mania, Am J Psychiatry, 164, 1547, 10.1176/appi.ajp.2007.06111932 · DOI · Paper page
- Grande, 2014, Antipsychotic switching in bipolar disorders: asystematic review, Int J Neuropsychopharmacol, 17, 497, 10.1017/S1461145713001168 · DOI · Paper page
- Dusetzina, 2012, Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents, Pharmacother, 32, 1085, 10.1002/phar.1148 · DOI
- Kowatch, 2005, Treatment guidelines for children and adolescents with bipolar disorder, J Am Acad Child Adolesc Psychiatry, 44, 213, 10.1097/00004583-200503000-00006 · DOI · Paper page
- Costall, 1990, Actions of ORG 5222 as a novel psychotropic agent, Pharmacol Biochem Behav, 35, 607, 10.1016/0091-3057(90)90298-V · doi:10.1016/0091-3057(90)90298-v
- McIntyre, 2010, Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder, Expert Rev Neurother, 10, 645, 10.1586/ern.10.49 · DOI
- Tarazi, 2013, The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania, Expert Opin Drug Discov, 8, 93, 10.1517/17460441.2013.738193 · DOI
- Shahid, 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature, J Psychopharmacol, 23, 65, 10.1177/0269881107082944 · DOI · Paper page
- McIntyre, 2009, A 3-week, randomized, PBO-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states, Bipolar Disord, 11, 673, 10.1111/j.1399-5618.2009.00748.x · DOI · Paper page
- McIntyre, 2010, Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, PBO-controlled trial, J Affect Disord, 122, 27, 10.1016/j.jad.2009.12.028 · DOI · Paper page
- Haas, 2009, Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study, Bipolar Disord, 11, 687, 10.1111/j.1399-5618.2009.00750.x · DOI · Paper page
- Firstad, 1992, The Mania Rating Scale: can it be used in children? A preliminary report, J Am Acad Child Adolesc Psychiatry, 31, 252, 10.1097/00004583-199203000-00011 · DOI · Paper page
- Youngstrom, 2002, Factor structure for the young mania rating scale for use with youths ages 5 to 17 years, J Clin Child Adolesc Psychol, 31, 567, 10.1207/S15374424JCCP3104_15 · doi:10.1207/s15374424jccp3104_15 · Paper page
- Poznanski, 1979, A depression rating scale for children, Pediatrics, 64, 441, 10.1542/peds.64.4.442 · DOI · Paper page
- Poznanski, 1985, Diagnostic criteria in childhood depression, Am J Psychiatry, 142, 1168, 10.1176/ajp.142.10.1168 · DOI · Paper page
- Jain, 2007, A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children, J Am Acad Child Adolesc Psychiatry, 46, 1204, 10.1097/chi.0b013e3180cc2575 · DOI
- Chouinard, 2005, Manual for the Extrapyramidal Symptom Rating Scale (ESRS), Schizophrenia Res, 76, 247, 10.1016/j.schres.2005.02.013 · DOI · Paper page
- Mietinnen, 1985, Comparative analysis of two rates, Stat Med, 4, 213, 10.1002/sim.4780040211 · DOI · Paper page
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
DelBello, M. P., Goldman, R., Phillips, D., Deng, L., Cucchiaro, J., & Loebel, A. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.10.006 · Cited by 135
Findling, R. L., Landbloom, R. L., Mackle, M., Wu, X., Snow-Adami, L., Chang, K., & Durgam, S. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0184-2 · Cited by 53
Self-citation
Metadata
- Authors
- Findling, R. L., Landbloom, R. L., Szegedi, A., Koppenhaver, J., Braat, S., Zhu, Q., Mackle, M., Chang, K., & Mathews, M.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 54
- Issue
- 12
- Pages
- 1032-1041
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W1859959435
- Cited by
- 104
- References
- 7
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.